Generic placeholder image

Current Pharmaceutical Design

Editor-in-Chief

ISSN (Print): 1381-6128
ISSN (Online): 1873-4286

Review Article

Pharmacotherapy of Myopic Choroidal Neovascularization

Author(s): Hacer Isildak, Stephen G. Schwartz* and Harry W. Flynn

Volume 24 , Issue 41 , 2018

Page: [4853 - 4859] Pages: 7

DOI: 10.2174/1381612825666190124102641

Price: $65

Abstract

Background: Myopic choroidal neovascularization (CNV) is a common cause of central visual loss in patients with high myopia, and the most common form of CNV in younger individuals. Pharmacologic therapy is the current mainstay of treatment of these patients.

Methods: Review of pharmacological treatment options for myopic CNV, which primarily involves intravitreal administration of anti-vascular endothelial growth factor (anti-VEGF) agents.

Results: At this time, anti-VEGF therapy agents are the first-line therapy in these patients. Comparative trials have not identified any major differences in treatment outcomes between aflibercept, bevacizumab, and ranibizumab. Only ranibizumab is approved for this indication in the US. Best visual outcomes are associated with younger age, smaller lesion size, and absence of chorioretinal atrophy.

Conclusion: Anti-VEGF therapy is generally very effective in the treatment of myopic CNV.

Keywords: Myopic choroidal neovascularization, pharmacotherapy, photodynamic therapy, verteporfin, anti-VEGF, bevacizumab, ranibizumab, aflibercept, pegaptanib.


Rights & Permissions Print Export Cite as
© 2022 Bentham Science Publishers | Privacy Policy